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ABSTRACT 
Type 2diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by disorders of insulin action and insulin secretion, and 
associated with increase problem of insulin resistant. High plasma levels of insulin and glucose due to insulin resistance often lead tometabolic 
syndrome. Chronic inflammation associated with metabolic and immune system involves a network of cellular andsystemic responses that 
integrates many complex signaling pathways infiltration of inflammation cells in adipose tissue , abnormal pro-inflammatory 
cytokinesproduction(IL-8,TNF-α). The study is designed to measure glycosylated hemoglobin (HbA1c),IL-8 and TNF-α.These parameters and 
measures applied for thirty newly diagnosed  patients with diabetes before and after treatment divided into 3 group.Three groups of (10) patients 
each newly diagnosed withT2DM;group(1) receives:500mg metformin for 3 months with (HbA1c=9.54±1.95,IL-8=13.85±6.15,TNF-α=260.1±123.7).                                        
group(2)receives:1000mg metformin for 3 months with (HbA1c=9.16±1.55,IL-8=15.02±6.28,TNF-α=230.86±49.26).    group(3)receives:1500mg 
metformin for 3 months with(HbA1c=9.80±1.94,IL-8=14.41±4.61,TNF-=207.42±40.45).                     
Blood samples were withdrawn from the patients at pretreatment,then after 3 months of treatment. After 3 months of  treatment, patient who 
received metformin 1500mg had greater reduction in  HbA1c,IL-8 and TNF-α(27,9%,44.20% and49.75% respectively),compared with patient who 
received metformin 1000mg(18.3%,15.77%,34.42% respectively)and to metformin 500mg(10.3%.12.56% and 4.72%). 
Metformin monotherapy are effective as an initial treatment of newly diagnosed diabetic patients in The national  diabetes center / University of Al-
Mustansiriyah, Iraq.Metformin has significant reduction effect on these three group, had significant reduction in HbA1c and also significant 
reduction in cytokines in the three dose in different percent. 
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INTRODUCTION 
The term diabetes mellitus (DM) describes a metabolic disorder of 
multiple aetiologies characterized chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action or both.[1]Factors 
that influence the development of chronic hyperglycaemia include 
genetic abnormalities; environmental causes, such as nutritional 
excess and lack of activity; increased hepatic production of glucose; 
increases in visceral fat; atherogenicdyslipidaemias; increased of 
oxidation and inflammation, natural processes involved in 
maintaining a physiologic state. Long-term complications associated 
with chronic hyperglycaemia include microvascular disease, such as 
retinopathy, nephropathy, neuropathy and macrovascular diseases, 
including fatal and non-fatal myocardial infarction, peripheral 
vascular disease and stroke [2].The goal of treatment is typically an 
HbA1C of less than 7% or a fasting glucose of less than 6.7 mmol/L 
(120 mg/dL) however these goals may be changed after professional 
clinical consultation, taking into account particular risks of 
hypoglycemia  and lifeexpectancy.[3]Type 1 DM is characterized by 
loss of the insulin-producing beta cells of the islets of Langerhans in 
the pancreas leading to a deficiency of insulin, while Type 2DM is 
characterized differently and is due to insulin resistance or reduced 
insulin sensitivity, combined with relatively reduced insulin 
secretion which in some cases becomes absolute.[4]Chronic 
inflammation associated with the metabolic and immune systems 
involves a network of cellular and systemic responses that integrate 
many complex signalling pathways.[5] Mediators of these pathways 
include major stress hormones, noradrenaline and adrenaline and 
cortisol; angiotensin-II (ang-II); pro-inflammatory cytokines.[6] 
Environmental factors plus a genetic predisposition can increase 
adiposity, which is associated with both a localised and systemic 
chronic inflammation characterised by infiltration of inflammatory 
cells in adipose tissue, abnormal pro-inflammatory cytokine  
 
production. This phenomenon, referred to as meta-inflammation 
(metabolic inflammation).[7] Recently, it has been reported that 
metformin activates AMPK in macrophages and this results in the 
inhibition of biosynthesis of phospholipids as well as neutral lipids 
and down-regulates the expression of LPS-inducedpro-inflammatory 
cytokines.[8]metformin has suppressed IL-8 release from human 
adipose tissue in vitro, [9]Thus, metformin seems to exert its anti-
inflammatory role by reducing pro-inflammatory cytokine secretion 
in specific cell types.[9] 
Materials,Subjects and Methods 
The study was conducted between October 2012 up to March 2013; 
during this period Thirty Iraqi patients of newly diagnosed patient 
with type 2 diabetes  were attended of the (The National Diabetes 
Center  , University of Al-Mustansiriyah)Their age ranging (35-77) 
year's mean±SD (51.5±10.248) years.They had no history of 
smoking or alcohol drinking. The diagnosis of T2DM was made on 
the basis of the recommended criteria by WHO(1999).[1]The 
selected patient diabetic patients were treated with different doses 
of oral hypoglycemic agents (Glucophage ® (Metformin 500mg) 
tablets -Merck, France- 500, 1000, 1500 mg) according to the patient 
condition and the physician opinion and randomized into three 
groups: 
1- First group: includes (10) patient diabetic patients were treated 
with oral hypoglycemic agent metformin in a dose (500mg/day) for 
(3)months.2- Second group: includes  (10) patient diabetic patients 
were treated with metformin in a dose (1000 mg/day) for 
(3)months          .                
3- Third group: included  (10) patient diabetic patients were treated 
with metformin in a dose (1500mg/day) for (3) months. 
Vol 1, Issue 3 , 2013                               ISSN  2321-4406 
Yasser  et al. 




Ten ml of venous blood were drawn using a plastic disposable 
syringe of 10ml capacity. All patients were fasting (12-14) hr 
calories free diet.Two ml of blood collected in EDTA containing tubes 
for measurement of HbA1c.The remaining blood was allowed to clot 
and separated by centrifuge at speed of 3000 rpm for 20 minutes. 
Serum samples were stored at (-20 OC) until the time of examination 
for the other testesParametes used  for analysis involved:Estimation 
of  glycosylated hemoglobin ( HbA1c);Glycated hemoglobin was 
measured by using the Variant Hemoglobin A1C program developed 
by BIO-Rad.[10] 
Serum levels of cytokines ( IL-8 & TNF-α ) were quantitatively 
determined in patients  by means of sandwich ELISA test using 
commercially available kit                                                                
Statistical Analysis 
Data were statistically evaluated using paired t-test to compare 
between pre- and post-treatment results. Another  way analysis of 
variance (ANOVA)  was utilized to compare between the results of 
studied parameters among different patients groups.  Values with 
P<0.05 were considered significantly different.  
Results 
HbA1c:  
Effect of treatment with different doses of metformin on HbA1c level 
in newly diagnosed patient with type 2 DM 
Table – 1: showed that all T2DM patients treated with different 
doses of metformin (500, 1000 and 1500)mg showed significant 
decrease in HbA1c levels after 3 months  (P<0.05) using Paired t-test 
compared with pre-treatment values.However, the percent 
reduction  in HbA1c produced due to the use of different dosesof 
metformin (500, 1000 and 1500)mg were (10.3%, 18.3% and 
27.9%)respectively compared with baseline values; while the 
patient  groups treated  which was statically not Significant (P>0.05) 
according to ANOVA test as in (Table -1) and (Figure-1). 
 
Tab1: HbA1c distribution of newly diagnosed  diabetic type 2 patient treated with different dose of  metformin before and after 3 months. 
 Metformin 500 mg  Metformin1000 mg  Metformin1500 mg 




















P value compare After to Before 0.0001*  0.0001*  0.001* 
Before P value compare to 500mg -  0.635  0.768 
           P value compare to 1000mg -  -  0.425 
           P value comparing All doses     0.734 
After   P value compare to 500mg -  0.134  0.051 
           P value compare to 1000mg -  -  0.411 
           P value comparing All doses     0.072 
Data were presented as Mean±SD (Range) 
*Significant using Paired t-test for difference between two dependent means (paired observations) at 0.05 level 
#Significant using Student t-test for difference between two independent means at 0.05 level 
@Significant using ANOVA test for difference among three independent means at 0.05 level 
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Fig 1: HbA1c distribution of newly diagnosed  diabetic type 2 patient treated with different dose ofmetformin before and after 3 months.       
 
Interleukin -8  
Effect of treatment with different doses of metformin on Interleukin 
8  level in newly diagnosed patient with T2DM : 
Tab -2;   showed that there is a significant decrease in IL-8 in all 
groups of patients treated with different doses of metformin (500, 
1000 and 1500)mg after 3 months (P<0.05) compared with baseline 
values   according to  Paired t-test . Moreover, (table -2) and     
(figure -2) showed that treatment with maximum dose of metformin 
(1500mg) produced a higher percent reduction in this parameter 
after 3 months (-44.20 %) compared with base line values,  and 
metformin treated group (1000mg),(500mg)  produced  (-15.77% 
and -12.56% respectively). There is a significant difference among 
the three groups treated with metformin doses after 3 months 
(P<0.05), and also a significant according to ANOVA test  (P<0.05). 
 













Mean HbA1C%  Before
 
 Metformin 500 mg Metformin1000 mg  Metformin1500 mg 






















P value compare After to 
Before 
 0.018* 0.005*  0.004* 
Before P value compare 
to 500mg 
 - 0.899  0.820 
P value compare to 
1000mg 
 - -  0.807 
P value comparing All 
doses 
    0.901 
After   P value compare 
to 500mg 
 - 0.048#  0.018# 
P value compare to 
1000mg 
 - -  0.014# 
P value comparing All 
doses 
    0.039@ 
-Data were presented as Mean±SD (Range) 
*Significant using Paired t-test for difference between two dependent means (paired observations) at 0.05 level 
#Significant using Student t-test for difference between two independent means at 0.05 level 
@Significant using ANOVA test for difference among three independent means at 0.05 level 
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Effect of treatment with different doses of metformin on TNF- α  
level in newly diagnosed patient with type 2 DM : 
Tab -3:  showed that there is a significant decrease in  TNF- α   in all 
groups of patients treated with different doses of metformin (500, 
1000 and 1500)mg after 3 months (P<0.05) compared with baseline 
values   according to  Paired t-test . Moreover, table -3 and figure -3 
showed that treatment with maximum dose of metformin (1500mg) 
produced a higher percent reduction in this parameter after 3 
months (-49.75 %) compared with base line values,  and metformin 
treated group (1000mg),(500mg)  produced  (- 34.42 % and -4.72% 
respectively). There is a significant difference among the three 
groups treated with metformin doses after 3 months (P<0.05), and 
also a significant according to ANOVA test  (P<0.05).  
 
Tab 3:serum TNF- α  concentration of newly diagnosed  diabetic type 2 patient treated with different dose of metformin before  and after 
3 months  . 
 
Metformin 500 mg  Metformin1000 mg Metformin1500 
mg 
















P value compare After to Before 0.001*  0.002* 0.0001* 
Before P value compare to 500mg -  0.496 0.217 
           P value compare to 1000mg -  - 0.260 
           P value comparing All doses    0.354 
After   P value compare to 500mg -  0.040# 0.003# 
           P value compare to 1000mg -  - 0.025# 
           P value comparing All doses    0.002@ 
-Data were presented as Mean±SD (Range) 
*Significant using Paired t-test for difference between two dependent means (paired observations) at 0.05 level 
#Significant using Student t-test for difference between two independent means at 0.05 level 
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FIG -3: TNF-α  serum concentration of newly diagnosed  diabetic type 2 patient treated with different dose of metformin before and after 3 
months. 
DISCUSSION 
Many specialist recommended the use of metformin as first drug of 
choice in newly diagnosed diabetic patients in  The National 
Diabetes Center, University of Al-Mustansiriyahin Baghdad, strategy 
which was parallel to the strategy used in the treatment of diabetes 
mellitus in other countries.[11] Metformin lowers hyperglycemia by 
reducing hepatic gluconeogenesis in the present of insulin and 
increasing peripheral glucose uptake and utilization.[12,13,14]The 
results in the present study investigated the effects of different 
doses ofmetformin (500, 1000 and 1500)mg on HbA1c levels in 
newly diagnosedT2DM patients for periods of 3 months .The mean 
values of HbA1c intreated groups of diabetic patients are in 
agreement with other results.[15,16]However, the percent reduction 
in HbA1c produced following the use of differentdoses of metformin 
were (-10%,-18.3% and -28.2%)respectively compared with 
baseline values; This finding agrees with other previous studies 
[17,18,19] and thepossible explanation for these results could be 
attributed to the effect of the shortduration of treatment and also, 
the baseline values of HbA1c at zero time indifferent treated groups 
were lower than the fasting glucose values, which couldprobably 
reflect that the HbA1c values were not in steady state at the start 
oftreatment.[17,20] Moreover, (table -1) and (figure-1) showed that 
treatment with maximummetformin (1500mg) produced the highest 
percent reduction in thisparameter after 3 month rather than the 
other groups treated with 1000mgand 500mg doses compared with 
baseline values. These results are compatible  with those of Garber 
et al (1997),[21]who demonstrated that the hypoglycemic activityof 
metformin on glycemic control (%HbA1c) in diabetic patients is 
exhibited,generally, a dose-dependent manner.[21] High HbA1c 
regarded as predicator for the development of microangiopathy. 
This problem may be explained by the facts that HbA1c had high 
affinity for O2 resulting in marked difficulty in unloading of O2 to 
peripheral tissues resulting in tissue hypoxia and 
microangiopathy.[22]   
It is increasingly recognized that markers of vascular inflammation 
play a role in the pathogenesis of T2DM, insulin resistance, and 
atherosclerosis,[23]the infiltration of macrophages into fat tissue and 
their subsequent release of pro-inflammatory cytokines into 
circulation occur at a greater rate in type 2 diabetics than non-
diabetics[24,25,26] &pro-inflammatory cytokines clearly decrease 
insulin sensitivity.[27] The use of metformin during the first month of 
treatment of patient with coronary artery disease and T2DM  led to 
the decrease of insulin resistance and reduced activity  of  systemic 
inflammation (significant decrease in the concentration  of  IL-8 and 
TNF-α ).[28] The results in the present study investigated the effects 
of different doses of metformin (500, 1000 and 1500)mg on IL-8 
&TNF-α  levels in newly diagnosed T2DM patients for periods of 3 
months .The mean values of  IL-8 &TNF-α in treated groups of 
diabetic patients are in agreement with other results.[29,30,31] 
However, the percent of reduction in IL-8 &TNF-α  produced 
following the use of different doses of metformin were (-12.56%,-
15.77% and -44.20%) for  IL-8 ,(-4.72 %,-34.42%  and -49.75 %) for 
TNF-α  respectively compared with baseline values; This finding 
agrees with other previous studies[32,33] and the possible explanation 
for these results could be attributed to the effect of the short 
duration of treatment and also, the baseline values ofIL-8 & TNF-α in 
different treated groups were lower than that of newly diagnosed  
values, which could probably reflect that the IL-8 & TNF-α values 
were have significant decrease in the concentration  compared with 
baseline values.[28] Metformin can exert a direct vascular anti-
inflammatory effect by inhibiting NF-kappa B through blockade of 
the PI3K-Akt pathway. The novel anti-inflammatory actions of 
metformin may explain in part the apparent clinical reduction by 
metformin of cardiovascular events not fully attributable to its 
hypoglycemic action.[34]   
Moreover, (table -2,3) and (figure -) showed that treatment with 
maximumdose of metformin (1500mg) produced the highest 
percent reduction in thisparameter after 3 month rather than the 
other groups treated with 1000mgand 500mg doses compared with 
baseline values. These results are compatible  with those of 
YoshiyukiHattoriet al (2006)[33] who demonstrated that the effect of 
metformin on cytokine (IL-8 &TNF-α) in diabetic patients is 
exhibited, generally, a dose-dependent manner.[33]These results, 
therefore, should be discussed within this framework, and not 
necessarily to becomparable with other results. Furthermore, the 
exact mechanism action of metformin remains elusive.[35]On one 
hand, some experts consider metformin to be the drug of choice for 
newly diagnosed type 2 diabetics.[36] whereas the landmark Diabetes 
Prevention Program, on the other hand, concluded that metformin is 
efficacious in preventing the new onset of type 2 diabetes in middle-
aged, obese persons with impaired glucose tolerance and fasting  
hyperglycemia but did not prevent diabetes in older, leaner 
prediabetics.[35]Finally, the present study did establish an 
improved efficacy of metforminuse at different doses (500-
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weeks of treatment. Furthermore, this study demonstrated an 
improvedinsulin sensitivity of metformin&pro-inflammatory 
cytokines clearly decrease insulin sensitivity in the newly diagnosed 
type 2 diabetic patients.The current study was conducted on a small 
number of patients, and no powercalculation was done, because of 
the paucity of data, on dose calculation ofmetformin in newly 
diagnosed diabetic patient. Therefore, the number of patientswas 
too small to draw a strong conclusion from it, and a larger number of 
patientsare essential for a better understanding of the present 
results. 
CONCLUSION 
 The use of different doses of metformin as amonotherapy 
in all treated groups significantlyimproved the  
biochemical markers (HbA1c) in newly diagnosed patient 
with type2 diabetes. 
 Serum levels of the inflammatory marker( IL-8 and  TNF-
α) are          decreased in all treated groups with different 
doses  of  metformin after 3 months in different percent of 
reduction; metformin has anti- inflammatory effect. 
 We demonstrated that metformin inhibits the expression 
of proinflammatoryresulting in suppression of cytokine-
induced NF-κB activation.  the present results suggest that 
metformin may serve for antiatherogenic drug for 
diabetic subjects. 
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